These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21633047)

  • 1. Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer.
    Buzdar AU; Xu B; Digumarti R; Goedhals L; Hu X; Semiglazov V; Cheporov S; Gotovkin E; Hoersch S; Rittweger K; Miles DW; O'Shaughnessy J; Tjulandin S;
    Ann Oncol; 2012 Mar; 23(3):589-597. PubMed ID: 21633047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.
    Yamamoto D; Sato N; Rai Y; Yamamoto Y; Saito M; Iwata H; Masuda N; Oura S; Watanabe J; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Feb; 161(3):473-482. PubMed ID: 28005247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
    Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
    Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
    Silva O; Lopes G; Morgenzstern D; Lobo C; Doliny P; Santos E; Abdullah S; Gautam U; Reis I; Welsh C; Slingerland J; Hurley J; Gluck S
    Clin Breast Cancer; 2008 Apr; 8(2):162-7. PubMed ID: 18621613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
    Leonard R; O'Shaughnessy J; Vukelja S; Gorbounova V; Chan-Navarro CA; Maraninchi D; Barak-Wigler N; McKendrick JJ; Harker WG; Bexon AS; Twelves C
    Ann Oncol; 2006 Sep; 17(9):1379-85. PubMed ID: 16966367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.
    Mavroudis D; Papakotoulas P; Ardavanis A; Syrigos K; Kakolyris S; Ziras N; Kouroussis C; Malamos N; Polyzos A; Christophyllakis C; Kentepozidis N; Georgoulias V;
    Ann Oncol; 2010 Jan; 21(1):48-54. PubMed ID: 19906761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer.
    Wildiers H; Neven P; Christiaens MR; Squifflet P; Amant F; Weltens C; Smeets A; van Limbergen E; Debrock G; Renard V; Van Eenoo L; Wynendaele W; Paridaens R
    Ann Oncol; 2011 Mar; 22(3):588-594. PubMed ID: 20709813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.
    Perez EA; Hillman DW; Dentchev T; Le-Lindqwister NA; Geeraerts LH; Fitch TR; Liu H; Graham DL; Kahanic SP; Gross HM; Patel TA; Palmieri FM; Dueck AC
    Ann Oncol; 2010 Feb; 21(2):269-274. PubMed ID: 19901014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer.
    Jinno H; Sakata M; Hayashida T; Takahashi M; Mukai M; Ikeda T; Kitagawa Y
    Ann Oncol; 2010 Jun; 21(6):1262-1266. PubMed ID: 19854722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
    Bayo J; Lomas M; Salvador J; Moreno A; Ruiz M; Rodríguez A; Fuentes J; Fernández-Freire A; Bernabé R; Fernández A
    Clin Transl Oncol; 2008 Dec; 10(12):817-25. PubMed ID: 19068453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
    Chan S; Romieu G; Huober J; Delozier T; Tubiana-Hulin M; Schneeweiss A; Lluch A; Llombart A; du Bois A; Kreienberg R; Mayordomo JI; Antón A; Harrison M; Jones A; Carrasco E; Vaury AT; Frimodt-Moller B; Fumoleau P
    J Clin Oncol; 2009 Apr; 27(11):1753-60. PubMed ID: 19273714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
    Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
    Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
    Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
    Michalaki V; Gennatas S; Gennatas K
    Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
    Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
    Nuzzo F; Morabito A; Gravina A; Di Rella F; Landi G; Pacilio C; Labonia V; Rossi E; De Maio E; Piccirillo MC; D'Aiuto G; Thomas R; Rinaldo M; Botti G; Di Bonito M; Di Maio M; Gallo C; Perrone F; de Matteis A
    BMC Cancer; 2011 Feb; 11():75. PubMed ID: 21324184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
    Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
    Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.
    Bachelot T; Bajard A; Ray-Coquard I; Provencal J; Coeffic D; Agostini C; Boisseau M; Kaphan R; Dramais D; Oprea C; Ferri-Dessens RM; Guastalla JP; Perol D
    Oncology; 2011; 80(3-4):262-8. PubMed ID: 21734418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
    Van Cutsem E; Boni C; Tabernero J; Massuti B; Middleton G; Dane F; Reichardt P; Pimentel FL; Cohn A; Follana P; Clemens M; Zaniboni A; Moiseyenko V; Harrison M; Richards DA; Prenen H; Pernot S; Ecstein-Fraisse E; Hitier S; Rougier P
    Ann Oncol; 2015 Jan; 26(1):149-156. PubMed ID: 25416687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
    Puglisi F; Cardellino GG; Crivellari D; Di Loreto C; Magri MD; Minisini AM; Mansutti M; Andreetta C; Russo S; Lombardi D; Perin T; Damante G; Veronesi A
    Ann Oncol; 2008 Sep; 19(9):1541-6. PubMed ID: 18441329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.